Literature DB >> 24128675

Abnormal gephyrin immunoreactivity associated with Alzheimer disease pathologic changes.

Chadwick M Hales1, Howard Rees, Nicholas T Seyfried, Eric B Dammer, Duc M Duong, Marla Gearing, Thomas J Montine, Juan C Troncoso, Madhav Thambisetty, Allan I Levey, James J Lah, Thomas S Wingo.   

Abstract

Many neurodegenerative disorders involve the abnormal accumulation of proteins. In addition to the pathologic hallmarks of neurofibrillary tangles and β-amyloid plaques in Alzheimer disease (AD), here we show that abnormal accumulations of gephyrin, an inhibitory receptor-anchoring protein, are highly correlated with the neuropathologic diagnosis of AD in 17 AD versus 14 control cases. Furthermore, gephyrin accumulations were specific for AD and not seen in normal controls or other neurodegenerative diseases including Parkinson disease, corticobasal degeneration, and frontotemporal degeneration. Gephyrin accumulations in AD overlapped with β-amyloid plaques and, more rarely, neurofibrillary tangles. Biochemical and proteomic studies of AD and control brain samples suggested alterations in gephyrin solubility and reveal elevated levels of gephyrin lower-molecular-weight species in the AD insoluble fraction. Because gephyrin is involved in synaptic organization and synaptic dysfunction is an early event in AD, these findings point to its possible role in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24128675      PMCID: PMC4037931          DOI: 10.1097/01.jnen.0000435847.59828.db

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  31 in total

1.  Dual requirement for gephyrin in glycine receptor clustering and molybdoenzyme activity.

Authors:  G Feng; H Tintrup; J Kirsch; M C Nichol; J Kuhse; H Betz; J R Sanes
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

2.  Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum.

Authors:  D Campion; C Dumanchin; D Hannequin; B Dubois; S Belliard; M Puel; C Thomas-Anterion; A Michon; C Martin; F Charbonnier; G Raux; A Camuzat; C Penet; V Mesnage; M Martinez; F Clerget-Darpoux; A Brice; T Frebourg
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

3.  The Mr 93,000 polypeptide of the postsynaptic glycine receptor complex is a peripheral membrane protein.

Authors:  B Schmitt; P Knaus; C M Becker; H Betz
Journal:  Biochemistry       Date:  1987-02-10       Impact factor: 3.162

Review 4.  Neuropathological alterations in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

5.  Biochemical characterization of the high affinity binding between the glycine receptor and gephyrin.

Authors:  Nils Schrader; Eun Young Kim; Jan Winking; Jens Paulukat; Hermann Schindelin; Günter Schwarz
Journal:  J Biol Chem       Date:  2004-02-19       Impact factor: 5.157

Review 6.  Mutations in the molybdenum cofactor biosynthetic genes MOCS1, MOCS2, and GEPH.

Authors:  Jochen Reiss; Jean L Johnson
Journal:  Hum Mutat       Date:  2003-06       Impact factor: 4.878

7.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

8.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

9.  Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease.

Authors:  Yair M Gozal; Duc M Duong; Marla Gearing; Dongmei Cheng; John J Hanfelt; Christopher Funderburk; Junmin Peng; James J Lah; Allan I Levey
Journal:  J Proteome Res       Date:  2009-11       Impact factor: 4.466

10.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

View more
  14 in total

1.  Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease.

Authors:  Srikant Rangaraju; Marla Gearing; Lee-Way Jin; Allan Levey
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  New approach to capture and characterize synaptic proteome.

Authors:  Xin-An Liu; Beena Kadakkuzha; Bruce Pascal; Caitlin Steckler; Komolitdin Akhmedov; Long Yan; Michael Chalmers; Sathyanarayanan V Puthanveettil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-28       Impact factor: 11.205

Review 3.  Gephyrin: a key regulatory protein of inhibitory synapses and beyond.

Authors:  Femke L Groeneweg; Christa Trattnig; Jochen Kuhse; Ralph A Nawrotzki; Joachim Kirsch
Journal:  Histochem Cell Biol       Date:  2018-09-27       Impact factor: 4.304

4.  Complex regulation of Gephyrin splicing is a determinant of inhibitory postsynaptic diversity.

Authors:  Fabrice Ango; Eric Allemand; Raphaël Dos Reis; Etienne Kornobis; Alyssa Pereira; Frederic Tores; Judit Carrasco; Candice Gautier; Céline Jahannault-Talignani; Patrick Nitschké; Christian Muchardt; Andreas Schlosser; Hans Michael Maric
Journal:  Nat Commun       Date:  2022-06-18       Impact factor: 17.694

5.  Dihydromyricetin ameliorates behavioral deficits and reverses neuropathology of transgenic mouse models of Alzheimer's disease.

Authors:  Jing Liang; Héctor E López-Valdés; Hilda Martínez-Coria; A Kerstin Lindemeyer; Yi Shen; Xuesi M Shao; Richard W Olsen
Journal:  Neurochem Res       Date:  2014-04-13       Impact factor: 3.996

6.  Increased excitatory to inhibitory synaptic ratio in parietal cortex samples from individuals with Alzheimer's disease.

Authors:  Julie C Lauterborn; Pietro Scaduto; Conor D Cox; Anton Schulmann; Gary Lynch; Christine M Gall; C Dirk Keene; Agenor Limon
Journal:  Nat Commun       Date:  2021-05-10       Impact factor: 14.919

7.  Human gephyrin is encompassed within giant functional noncoding yin-yang sequences.

Authors:  Sharlee Climer; Alan R Templeton; Weixiong Zhang
Journal:  Nat Commun       Date:  2015-03-27       Impact factor: 14.919

8.  Identification of Differentially Expressed Genes through Integrated Study of Alzheimer's Disease Affected Brain Regions.

Authors:  Nisha Puthiyedth; Carlos Riveros; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

Review 9.  Tuning GABAergic Inhibition: Gephyrin Molecular Organization and Functions.

Authors:  Rocco Pizzarelli; Marilena Griguoli; Paola Zacchi; Enrica Maria Petrini; Andrea Barberis; Antonino Cattaneo; Enrico Cherubini
Journal:  Neuroscience       Date:  2019-07-26       Impact factor: 3.590

Review 10.  Structure-Function Relationships of Glycine and GABAA Receptors and Their Interplay With the Scaffolding Protein Gephyrin.

Authors:  Vikram B Kasaragod; Hermann Schindelin
Journal:  Front Mol Neurosci       Date:  2018-09-12       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.